August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
August 29th 2025
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
August 22nd 2025
New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.
August 22nd 2025
STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.
August 21st 2025
First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.
Novavax COVID-19 Vaccine Linked to Fewer Adverse Effects in Health Care Workers and First Responders
April 28th 2025At ESCMID Global 2025, SHIELD study data show Novavax recipients experienced fewer adverse effects and missed less work compared with those who received the Pfizer-BioNTech COVID-19 vaccine.
Watch
For Children and Adolescents, COVID-19 Carries Higher Risk For Cardiovascular Outcomes
April 17th 2025A large study showed these SARS-CoV-2 positive groups were more prone to myocarditis, heart failure, arrhythmias, and chest pain—regardless of prior cardiovascular history or presence of congenital heart disease (CHD).
Read More
Nirmatrelvir-Ritonavir Shows Efficacy for Long COVID, But Lacks Significant Health Improvements
April 10th 2025A new phase 2 trial raises questions about nirmatrelvir-ritonavir’s broader efficacy, as other studies highlight its effectiveness in reducing mortality among immunocompromised COVID-19 patients.
Read More
Pandemic Public Health Policy and Trust: Did We Lose the Latter Through the Former’s Actions?
March 27th 2025In the second installment of our interview with Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), he discusses some of the takeaways in how public health messaging was lost on the public, which lead to mistrust, and thus leaving open the door for disinformation and misinformation.
Watch
With the Rise of COVID-19 Vaccines, a Greater Public Mistrust of Immunizations Has Taken Hold
March 25th 2025In the second installment of our COVID-19 pandemic series, Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), discusses the paradox that has arisen from the COVID-19 vaccines that in spite of their development in record time, what remains is a deeper mistrust in immunizations overall.
Watch
The COVID-19 Pandemic: Significance of Screening and Industry's Response
March 20th 2025This is the first in a series on the 5 year anniversary of the pandemic. We want to cover a variety of aspects around it, including lessons learned such as testing, vaccine development, and public health policy as well as some ongoing challenges that remain including vaccine hesitancy and an increase in antimicrobial resistant infections.
Read More
Pandemic Disruptions in HIV Care Impacted on Early ART Initiation and Viral Suppression
March 13th 2025Sarita Shah, MD, MPH, reveals a decline in timely ART initiation from 86.5% in 2019 to 83.9% in 2020, with viral suppression rates dropping from 91.1% to 84.7%, before showing signs of recovery by 2021.
Read More
2 Commerce Drive
Cranbury, NJ 08512